COLOCALIZATION OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE AND MINERALOCORTICOID RECEPTORS IN CULTURED VASCULAR SMOOTH-MUSCLE CELLS

被引:71
作者
KORNEL, L
机构
[1] From Steroid Research Laboratory, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL
关键词
ARTERIAL MINERALOCORTICOID RECEPTORS; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; CULTURED VASCULAR SMOOTH MUSCLE CELLS; RABBIT AORTA;
D O I
10.1093/ajh/7.1.100
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Colocalization of mineralocorticoid receptors (MR) and 11 beta-hydroxysteroid dehydrogenase (11-HSD), the enzyme acting as a protector of MR, in the same cell of mineralocorticoid (MC)-responsive tissues is crucial to the concept of enzymic regulation of intracellular cortisol levels in these tissues. Such colocalization was demonstrated in the epithelial cells of the renal distal tubule. The aim of the present study was to examine if MR and 11-HSD activity can be colocalized in cells of another target tissue to mineralocorticoids, the arteries. Vascular smooth muscle (VSM) cells were cultured, and absence of dedifferentiation was ascertained up to the eighth passage. High affinity binding of [H-3]-aldosterone (ALDO) was demonstrated in the intact cultured cells, and K-d and B-max values were calculated from Scatchard plots. The activity of 11-HSD was demonstrated in the cultured cells by incubating them with [H-3]-cortisol in the presence of cofactors, and isolating [H-3]-cortisone. Other [H-3]-metabolites formed were 11 beta-hydroxy- and 11-keto-androstenedione. These data support the view that arterial tree is a target organ for mineralocorticoids and may be of importance in the pathogenetic mechanism of MC-induced hypertension.
引用
收藏
页码:100 / 103
页数:4
相关论文
共 21 条
  • [1] Ulick S., Levine L.S., Rauh W., Et al., A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol, J Clin Endocrinol, 49, pp. 757-764, (1979)
  • [2] Monder C., Shackleton C., Bradlow L., Et al., The syndrome of apparent mineralocorticoid excess: Its association with 11β-dehydrogenase and 5β-reductase deficiency and some consequences for corticosteroid metabolism, J Clin Endocrinol, 63, pp. 550-557, (1986)
  • [3] Stewart P.M., Corrie J., Shackleton C., Edwards C., Syndrome of apparent mineralocorticoid excess: A defect in the cortisol-cortisone shuttle, J Clin Invest, 82, pp. 340-352, (1988)
  • [4] Edwards C., Stewart P.M., Burt D., Et al., Localization of 11β-hydroxysteroid dehydrogenase: Tissue-specific protector of the mineralocorticoid receptor, Lancet, 2, pp. 986-988, (1988)
  • [5] Funder J.W., Pearce P.T., Smith R., Smith A.I., Mineralo-corticoid action: Target tissue specificity is enzyme, not receptor, mediated, Science, 242, pp. 583-585, (1989)
  • [6] Naray-Fejes-toth A., Watlington C.O., Fejes-Toth G., 11β-Hydroxy steroid dehydrogenase activity in the renal target cells of aldosterone, Endocrinology, 129, pp. 17-21, (1991)
  • [7] Mercer W.R., Krozowski Z.S., Localization of an 11β-hydroxysteroid dehydrogenase activity to the distal nephron. Evidence for the existence of two species of dehydrogenase in the rat kidney, Endocrinology, 130, pp. 540-543, (1992)
  • [8] Kornel L., Studies on the mechanism of mineralocorticoid hypertension: Evidence for the presence of in situ mechanism in the arterial wall for a direct action of mineralocorticoids, Clin Biochem, 14, pp. 282-293, (1981)
  • [9] Kornel L., Kanamarlapudi N., Travers T., Et al., Studies on high affinity binding of mineralo- and glucocorticoids in rabbit aorta cytosol, J Steroid Biochem, 16, pp. 245-264, (1982)
  • [10] Kornel L., Ramsay C., Kanamarlapudi N., Et al., Evidence for the presence in arterial walls of intracellular-molecular mechanism for action of mineralocorticoids, Clin Exp Hypertens, 4, pp. 1561-1582, (1982)